+

RS20070364A - New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal - Google Patents

New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal

Info

Publication number
RS20070364A
RS20070364A RSP-2007/0364A RSP20070364A RS20070364A RS 20070364 A RS20070364 A RS 20070364A RS P20070364 A RSP20070364 A RS P20070364A RS 20070364 A RS20070364 A RS 20070364A
Authority
RS
Serbia
Prior art keywords
rifaximin
production
medicinal
polymorphous forms
processes
Prior art date
Application number
RSP-2007/0364A
Other languages
English (en)
Inventor
Manuela Campana
Dario Braga
Donatella Confortini
Giuseppe Claudio Viscomi
Maria Miriam Barbanti
Original Assignee
Alfa Wassermann S.P.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34934045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20070364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann S.P.A., filed Critical Alfa Wassermann S.P.A.,
Publication of RS20070364A publication Critical patent/RS20070364A/sr
Publication of RS54570B1 publication Critical patent/RS54570B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
    • C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
    • C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cilj predmetnog pronalaska su kristalni polimorfni oblici antibiotika rifaksimina (INN), koji su označeni kao rifaksimin δ i rifaksimin ε, koji su korisni u proizvodnji medicinskih preparata koji sadrže rifaksimin za oralnu i topijsku primenu i dobijaju se postupkom kristalizacije, koja podrazumeva rastvaranje sirovog rifaksimina u vrućem etil alkoholu i izazivanje kristalizacije proizvoda dodavanjem vode na određenoj temp. i tokom određenog vremena, a nakon toga se sušenje izvodi pod kontrolisanim uslovima dok se ne postigne željeni sadržaj vode u krajnjem proizvodu.
RS20070364A 2005-03-03 2006-02-27 Novi polimorfni oblici rifaksimina, postupak njihove proizvodnje i njihova upotreba u medicinskim preparatima RS54570B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05004695.2A EP1698630B1 (en) 2005-03-03 2005-03-03 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
PCT/EP2006/001755 WO2006094662A1 (en) 2005-03-03 2006-02-27 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal

Publications (2)

Publication Number Publication Date
RS20070364A true RS20070364A (en) 2009-01-22
RS54570B1 RS54570B1 (sr) 2016-06-30

Family

ID=34934045

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20070364A RS54570B1 (sr) 2005-03-03 2006-02-27 Novi polimorfni oblici rifaksimina, postupak njihove proizvodnje i njihova upotreba u medicinskim preparatima

Country Status (28)

Country Link
US (9) US8193196B2 (sr)
EP (1) EP1698630B1 (sr)
JP (2) JP5737825B2 (sr)
KR (1) KR100885755B1 (sr)
CN (1) CN1900077B (sr)
AU (1) AU2006222312B8 (sr)
BR (1) BRPI0608073A8 (sr)
CA (1) CA2594789C (sr)
DK (1) DK1698630T3 (sr)
ES (1) ES2522895T3 (sr)
HK (1) HK1096396A1 (sr)
HR (1) HRP20070433B1 (sr)
IL (1) IL184694A0 (sr)
MA (1) MA29345B1 (sr)
MD (1) MD4081G2 (sr)
ME (1) ME00272B (sr)
MX (1) MX2007010742A (sr)
NO (1) NO342197B1 (sr)
NZ (1) NZ556737A (sr)
PL (1) PL1698630T3 (sr)
PT (1) PT1698630E (sr)
RS (1) RS54570B1 (sr)
RU (1) RU2397985C2 (sr)
SI (1) SI1698630T1 (sr)
TN (1) TNSN07292A1 (sr)
UA (1) UA89809C2 (sr)
WO (1) WO2006094662A1 (sr)
ZA (1) ZA200707397B (sr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
PL1698630T3 (pl) * 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101480732B1 (ko) 2006-09-22 2015-01-21 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
EA201370208A1 (ru) 2008-02-25 2014-06-30 Сэликс Фармасьютиклз, Лтд. Формы рифаксимина и их применение
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
CA2716578A1 (en) 2008-02-26 2009-09-03 Salix Pharmaceuticals, Ltd. Use of rifaximin in subjects having diarrhea-predominant irritable bowel syndrome
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
SI3628319T1 (sl) 2008-10-02 2024-04-30 Salix Pharmaceuticals, Ltd. Zdravljenje jetrne encefalopatije z rifaksiminom
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
CA2773982C (en) 2009-09-13 2018-12-04 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP3650022A1 (en) 2010-02-18 2020-05-13 Salix Pharmaceuticals, Ltd. Methods for treating rifampin resistant clostridium difficilis infections
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN101836959A (zh) * 2010-05-20 2010-09-22 山东达因海洋生物制药股份有限公司 一种制备几乎无苦味利福昔明干混悬剂的方法
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
HUE049986T2 (hu) 2010-07-12 2020-11-30 Salix Pharmaceuticals Inc Rifaximin készítmények és ezek alkalmazásai
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
PT2672970T (pt) 2011-02-11 2018-10-11 Salix Pharmaceuticals Ltd Formas de rifaximina e suas utilizações
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2986825T3 (es) * 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
KR20150129691A (ko) 2013-03-15 2015-11-20 알파 와셔만 에스.피.아. 질 감염증의 치료에 사용하기 위한 리팍시민
PL2983647T3 (pl) 2013-04-12 2021-01-25 Alfasigma S.P.A. Podawanie nlpz oraz związane z tym składniki, sposoby i układy
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US9736829B2 (en) * 2013-10-14 2017-08-15 Qualcomm Incorporated Downlink control management in an unlicensed or shared spectrum
EP2927235B1 (en) * 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2946101A1 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
PT3143027T (pt) 2014-05-12 2019-09-20 Alfasigma Spa Nova forma de cristal solvatado de rifaximina, produção, composições e utilização dos mesmos
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
EP3294270B1 (en) 2016-03-24 2018-09-12 Sandoz AG Pharmaceutical composition containing rifaximin alpha&delta
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
KR20240124428A (ko) 2016-09-30 2024-08-16 샐릭스 파마슈티컬스 인코포레이티드 리팍시민의 고체 분산물 형태
US11052071B2 (en) 2017-04-26 2021-07-06 Sandoz Ag Oral dosage form comprising rifaximin in form beta
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine
DK3645539T3 (da) 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
AU2020355603A1 (en) 2019-09-24 2022-03-17 Bausch Health Ireland Limited Rifaximin liquid formulations
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021260211A1 (en) 2020-06-26 2021-12-30 Bausch Health Ireland Limited Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751182A (fr) 1969-05-30 1970-11-03 Takeda Chemical Industries Ltd Procede de fabrication d'antibiotiques
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
WO1992000302A1 (en) * 1990-06-29 1992-01-09 Gruppo Lepetit S.P.A. Pure crystalline form of rifapentine
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6271001B1 (en) 1995-03-23 2001-08-07 Bio Polymers Pty. Ltd. Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
WO1998016111A1 (en) 1996-10-16 1998-04-23 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
PL361912A1 (en) * 2000-10-31 2004-10-04 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ATE275405T1 (de) 2001-05-03 2004-09-15 Farmigea Spa Sucralfat enthaltendes arzneimittel zur behandlung von zervikale erosion
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1512404B1 (en) 2002-06-03 2009-10-21 Cac Corporation External preparations for treating dermatitis
RU2223764C1 (ru) * 2002-07-16 2004-02-20 Закрытое акционерное общество "АИП-Наука" Способ получения липосомальной формы рифампицина
CZ13908U1 (cs) 2003-10-08 2004-01-05 Cpn Spol. S R.O. Kosmetický přípravek s vysokomolekulární antioxidační složkou
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2006008512A2 (en) 2004-07-16 2006-01-26 Cipla Limited Anti-histaminic composition
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101480732B1 (ko) 2006-09-22 2015-01-21 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2905795T3 (es) 2007-07-06 2022-04-12 Lupin Ltd Composiciones farmacéuticas de rifaximina
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP2010259452A (ja) * 2007-08-21 2010-11-18 Konica Minolta Medical & Graphic Inc 画像診断支援装置及び画像診断支援方法
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
EA201370208A1 (ru) 2008-02-25 2014-06-30 Сэликс Фармасьютиклз, Лтд. Формы рифаксимина и их применение
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CA2716578A1 (en) 2008-02-26 2009-09-03 Salix Pharmaceuticals, Ltd. Use of rifaximin in subjects having diarrhea-predominant irritable bowel syndrome
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
SI3628319T1 (sl) 2008-10-02 2024-04-30 Salix Pharmaceuticals, Ltd. Zdravljenje jetrne encefalopatije z rifaksiminom
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
JP5276505B2 (ja) * 2009-04-06 2013-08-28 株式会社ユニバーサルエンターテインメント 遊技機
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CA2765577A1 (en) 2009-06-15 2010-12-23 William Forbes Modulation of systemic exposure to rifaximin
CA2773982C (en) 2009-09-13 2018-12-04 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
PT2493471T (pt) 2009-10-26 2020-01-09 Borody Thomas J Nova terapia de combinação entérica
EP2493456B1 (en) 2009-10-27 2018-11-21 Lupin Limited Solid dispersion of rifaximin
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
EP2503988A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
EP3650022A1 (en) 2010-02-18 2020-05-13 Salix Pharmaceuticals, Ltd. Methods for treating rifampin resistant clostridium difficilis infections
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP6092629B2 (ja) 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミン使用準備済懸濁液
EP2380961B1 (en) 2010-04-23 2018-05-23 The Procter and Gamble Company Detergent composition
MX2012013945A (es) 2010-06-03 2013-05-06 Salix Pharmaceuticals Ltd Nuevas formas de rifaximina y usos de las mismas.
WO2011156897A2 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
HUE049986T2 (hu) 2010-07-12 2020-11-30 Salix Pharmaceuticals Inc Rifaximin készítmények és ezek alkalmazásai
US20130315988A1 (en) 2010-09-13 2013-11-28 Cipla Limited Pharmaceutical Composition
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
PT2672970T (pt) 2011-02-11 2018-10-11 Salix Pharmaceuticals Ltd Formas de rifaximina e suas utilizações
WO2012150561A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2986825T3 (es) 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
WO2013112809A2 (en) 2012-01-25 2013-08-01 Salix Pharmaceuticals, Ltd Rifaximin derivative and uses thereof
JP2013184902A (ja) 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
PL2983647T3 (pl) 2013-04-12 2021-01-25 Alfasigma S.P.A. Podawanie nlpz oraz związane z tym składniki, sposoby i układy
CN105579458A (zh) 2013-05-17 2016-05-11 萨利克斯药品公司 在正电子发射断层摄影术(pet)扫描中使用利福昔明的方法
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
CA2946101A1 (en) 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
PT3143027T (pt) 2014-05-12 2019-09-20 Alfasigma Spa Nova forma de cristal solvatado de rifaximina, produção, composições e utilização dos mesmos
WO2016063289A2 (en) 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
WO2017021975A1 (en) 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
EP3294270B1 (en) 2016-03-24 2018-09-12 Sandoz AG Pharmaceutical composition containing rifaximin alpha&delta
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (en) 2017-03-02 2018-09-07 Granules India Limited Rifaximin crystalline form
WO2018178777A1 (en) 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
US11052071B2 (en) 2017-04-26 2021-07-06 Sandoz Ag Oral dosage form comprising rifaximin in form beta
DK3645539T3 (da) 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel

Also Published As

Publication number Publication date
US9271968B2 (en) 2016-03-01
ME00272B (me) 2011-05-10
US8193196B2 (en) 2012-06-05
US20200277301A1 (en) 2020-09-03
DK1698630T3 (da) 2014-12-08
ES2522895T3 (es) 2014-11-19
WO2006094662A1 (en) 2006-09-14
MD20070265A (en) 2008-05-31
EP1698630B1 (en) 2014-09-03
AU2006222312B2 (en) 2011-11-03
US20200002350A1 (en) 2020-01-02
MD4081F2 (en) 2010-12-31
EP1698630A1 (en) 2006-09-06
CN1900077B (zh) 2012-04-11
BRPI0608073A8 (pt) 2017-12-26
US20090130201A1 (en) 2009-05-21
NO342197B1 (no) 2018-04-16
BRPI0608073A2 (pt) 2009-11-03
US8518949B2 (en) 2013-08-27
MEP34408A (en) 2011-02-10
RS54570B1 (sr) 2016-06-30
KR20060096242A (ko) 2006-09-11
US20220119403A1 (en) 2022-04-21
ZA200707397B (en) 2009-03-25
PL1698630T3 (pl) 2014-12-31
US20150073007A1 (en) 2015-03-12
MD4081G2 (ro) 2011-07-31
CN1900077A (zh) 2007-01-24
HRP20070433B1 (hr) 2015-02-27
US10703763B2 (en) 2020-07-07
US20120245355A1 (en) 2012-09-27
MA29345B1 (fr) 2008-03-03
IL184694A0 (en) 2007-12-03
RU2397985C2 (ru) 2010-08-27
NO20074988L (no) 2007-11-30
JP2008531623A (ja) 2008-08-14
TNSN07292A1 (en) 2008-12-31
KR100885755B1 (ko) 2009-02-26
CA2594789C (en) 2010-09-14
MX2007010742A (es) 2007-09-12
SI1698630T1 (sl) 2015-01-30
US20130310410A1 (en) 2013-11-21
UA89809C2 (uk) 2010-03-10
PT1698630E (pt) 2014-09-15
CA2594789A1 (en) 2006-09-14
HRP20070433A2 (en) 2007-11-30
HK1096396A1 (en) 2007-06-01
EP1698630A8 (en) 2006-10-25
JP2013216710A (ja) 2013-10-24
AU2006222312B8 (en) 2011-11-17
US8741904B2 (en) 2014-06-03
JP5737825B2 (ja) 2015-06-17
US20180291032A1 (en) 2018-10-11
US20160362419A1 (en) 2016-12-15
AU2006222312A1 (en) 2006-09-14
NZ556737A (en) 2011-11-25
RU2007136430A (ru) 2009-04-10

Similar Documents

Publication Publication Date Title
RS20070364A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal
JO2470B1 (en) Polycrystalline image of rifaximin, processes for its production and use in medicinal preparations.
MX2009007730A (es) Polimorfos macrocilicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.
IN2015DN02325A (sr)
WO2009006590A3 (en) Docetaxel process and polymorphs
EP2436700B8 (en) Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
EP1896186A4 (en) METHOD FOR CONVERTING BULK MATERIAL
WO2010014883A3 (en) Azacitidine process and polymorphs
IL185780A0 (en) Process for the production of monoliths by means of the invert sol-gel process
AU2003298218A1 (en) Composition for controlled tempering by means of phase change, production and use thereof
EP2138505A4 (en) METHOD FOR PRODUCING HIGH-PURITY SOLUBLE THROMBOMODULINE
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2006122020A3 (en) Process for production of 4-biphenylyazetidin-2-ones
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir
MY143519A (en) Process for the production of ethers
SI1853220T1 (sl) Proizvodni postopek za pastile, ki vsebujejo nesteroidno protivnetno zdravilo (NSAID), njihovi sestavki in njihova medicinska uporaba
PL1686105T3 (pl) Sposób wytwarzania ogniotrwałych cegieł porowatych
WO2008056377A3 (en) Polymorphic forms of rimonabant
TW200700389A (en) 5h-benzocycloheptene derivatives, process for their production and their use as anti-inflammatory agents
IL178491A0 (en) Process for production of pyrazole-fused ring derivatives
WO2007034183A3 (en) Process for the preparation of 4-aminopyrazole derivatives
HK1089750A1 (en) A method for the preparation of crystalline dexloxiglumide
WO2004074305A3 (en) Process for the production of 2-oxa-3-one androstane derivatives
UA88108C2 (ru) Способ получения карбида кремния
AP1617A (en) Process for preparation of raw matooke (banana) flour
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载